Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSynthomer Regulatory News (SYNT)

Share Price Information for Synthomer (SYNT)

Share Price is delayed by 15 minutes
Get Live Data
100.00    -3.20 (-3.10%)
Bid:
100.40
Ask:
102.00
Spread: 1.60 (1.594%)
Market Cap: £163.94m
SYNT Live PriceLast checked at - London Stock Exchange

Intraday Synthomer Share Chart

Update

29 Dec 2008 07:00

RNS Number : 7991K
Yule Catto & Co PLC
29 December 2008
 



29 December 2008

Yule Catto & Co plc

Update

Yule Catto & Co plc ("the Group") is pleased to announce that it has signed a new three year £30 million revolving loan facility with its principal banks, HSBC and Barclays. This loan replaces its existing revolving bank loan facility maturing in November 2009.

During the course of this re-financing, the Board has been carefully considering the capital structure of the Group.  Whilst much progress has been made on the deleveraging of the balance sheet, with £55 million of gross proceeds received from the sale of three of our five Impact Chemicals businesses, the balance sheet remains a core focus of the Board and it aims to reduce outstanding net debt to below £100 million over the next twelve to twenty four months. The Board believes this is consistent with the Group's objectives, including its financial commitments to the Group's UK pension fund.

Accordingly, and in light of the current financial environment and economic uncertainty, the Board has additionally decided to suspend the payment of dividends until such time as net debt is nearer to its overall target and at which time the business environment and financial market conditions may well have improved. The Board anticipates reverting to the payment of a dividend within two years.

At the time the Group recommences the payment of a dividend, the Board anticipates rebasing it to a level determined by comparison with its peer group and which will allow an appropriate free cash flow to suit the Group's circumstances.

The Board is also pleased to confirm that for 2008 the Group still expects to deliver underlying earnings before tax modestly ahead of last year, despite the current difficult economic conditions particularly in the UK and Continental Europe.

The Board believes it is too early at this time, given the prevailing economic uncertainty, to offer any firm guidance on the outturn for 2009.  The Group's Impact Chemicals and Pharma Chemicals businesses should benefit next year from recent restructuring.  Within our Polymer Chemicals business we anticipate the performance of our Asian and Middle East businesses to be more robust than that of our European businesses, due to local market conditions and a more resilient demand profile from our targeted markets. In addition, the current relative weakness of Sterling against the Dollar, Euro and Malaysian Ringgit, should it continue, will assist the reported Sterling earnings for a number of our businesses.

The Group continues to look at ways to improve efficiency and minimise costs. We currently have a number of initiatives in hand to do this, both within Europe and the rest of the world. 

These are exceptional times, with a high degree of market uncertainty and a very difficult environment for funding.  Having completed £55 million of divestments and put in place a new revolving loanthe Board believes that, together with internal actions to conserve cash and the suspension of the dividend, Yule Catto is now well placed to weather these conditions.

- Ends -

For further information, please contact:

Yule Catto & Co plc
Adrian Whitfield, Chief Executive
David Blackwood, Group Finance Director
 
01279 442791
Hogarth Partnership 
John Olsen
Andrew Jaques
Ian Payne
020 7357 9477
07770 272082

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCFKQKNNBDDFBB
Date   Source Headline
26th Sep 20169:25 amRNSHolding(s) in Company
14th Sep 20163:10 pmRNSHolding(s) in Company
14th Sep 20163:01 pmRNSHolding(s) in Company
11th Aug 20161:15 pmRNSDisposal
9th Aug 20167:00 amRNSInterim Results for six months ended 30 June 2016
7th Jul 201611:50 amRNSHolding(s) in Company
7th Jul 201610:28 amRNSDirector/PDMR Shareholding
5th Jul 201611:57 amRNSHolding(s) in Company
1st Jul 20167:00 amRNSCompletion of acquisition and trading update
31st May 201611:31 amRNSAudit Tender
16th May 20164:17 pmRNSHolding(s) in Company
9th May 201612:31 pmRNSDirector/PDMR Shareholding
28th Apr 20163:11 pmRNSResult of AGM
28th Apr 20167:00 amRNSQ1 Trading update
21st Apr 20161:44 pmRNSHolding(s) in Company
20th Apr 20162:23 pmRNSDirector Declaration
11th Apr 20163:01 pmRNSDirector/PDMR Shareholding
11th Apr 20163:00 pmRNSDirector/PDMR Shareholding
31st Mar 20162:15 pmRNSAnnual Financial Report
21st Mar 20167:00 amRNSAcquisition
21st Mar 20167:00 amRNSDisposal
15th Mar 201612:29 pmRNSHolding(s) in Company
2nd Mar 20167:00 amRNSPreliminary Results for the year ended 31 Dec 2015
10th Feb 20167:00 amRNSFRS 101 Notification
5th Feb 20163:34 pmRNSHolding(s) in Company
5th Feb 20163:13 pmRNSHolding(s) in Company
30th Nov 20153:00 pmRNSHolding(s) in Company
18th Nov 201510:30 amRNSDirector/PDMR Shareholding
6th Nov 20157:00 amRNSQ3 Trading Update
1st Oct 201512:50 pmRNSHolding(s) in Company
13th Aug 201510:05 amRNSHolding(s) in Company
11th Aug 20157:00 amRNSHalf Yearly Results
10th Jul 20152:43 pmRNSDirector/PDMR Shareholding
9th Jul 20159:12 amRNSHolding(s) in Company
7th Jul 20154:21 pmRNSHolding(s) in Company
6th Jul 20153:59 pmRNSHolding(s) in Company
2nd Jul 20157:00 amRNSTrading Update
22nd Jun 20153:51 pmRNSHolding(s) in Company
20th May 20158:57 amRNSHolding(s) in Company
14th May 201510:02 amRNSDirector/PDMR Shareholding
30th Apr 201512:53 pmRNSResult of AGM
30th Apr 201512:46 pmRNSDirectorate Change
30th Apr 20157:00 amRNSQuarter 1 Trading Update
27th Apr 201510:36 amRNSDirectorate Change
21st Apr 20155:16 pmRNSHolding(s) in Company
1st Apr 20158:15 amRNSDirectorate Change
31st Mar 20159:25 amRNSAnnual Financial Report
30th Mar 201510:13 amRNSHolding(s) in Company
27th Mar 201512:53 pmRNSDirector/PDMR Shareholding
23rd Mar 20157:00 amRNSDirectorate Change

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.